FLTA3025: Dose-Related Increases in Pre-Dose FEV1 Were Seen with FP Treatment vs. Placebo

*P=0.010 vs PLA

*

Endpoint

(8%)

(5%)

? FEV1 (ml)

(2%)

Previous slide

Next slide

Back to first slide

View graphic version